Concerning Syfovre Approval for Geographic Atrophy

Author:

Publisher website

1 February 2024

journal article
editorial
Published by American Medical Association (AMA) in JAMA Ophthalmology

Vol. 142 (2) , 85-86
DOI:10.1001/jamaophthalmol.2023.5584
PMID:38060249

Abstract

This Viewpoint discusses concerns about Syfovre being approved as a treatment to slow the rate of geographic atrophy.

Keywords

This publication has 2 references indexed in Scilit:

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration
Ophthalmology, 2020
Natural History of Geographic Atrophy Progression Secondary to Age-Related Macular Degeneration (Geographic Atrophy Progression Study)
Ophthalmology, 2016